0

Filibuvir

INQUIRY Add to cart
For Research Use Only | Not For Clinical Use
CATAP877130284
CAS877130-28-4
Structure
Molecular Weight503.64
Description≥98% (HPLC)
SolubilityDMSO: 10 mg/mL, clear
Assay≥98% (HPLC)
Colorwhite to beige
Formpowder
Size5MG, 25MG
Storage Conditionsroom temp
1

Antiviral Activity of the Hepatitis C Virus Polymerase Inhibitor Filibuvir in Genotype 1-infected Patients

Frank Wagner, Robert Thompson, Constantino Kantaridis, Paul Simpson, Philip J F Troke, Shyla Jagannatha, Srividya Neelakantan, Vivek S Purohit, Jennifer L Hammond

Hepatology. 2011 Jul;54(1):50-9.

PMID: 21488067

1

Biophysical Mode-of-Action and Selectivity Analysis of Allosteric Inhibitors of Hepatitis C Virus (HCV) Polymerase

Eldar Abdurakhmanov, Sara Øie Solbak, U Helena Danielson

Viruses. 2017 Jun 16;9(6):151.

PMID: 28621755

1

Computational Study on the Drug Resistance Mechanism of HCV NS5B RNA-dependent RNA Polymerase Mutants V494I, V494A, M426A, and M423T to Filibuvir

Huiqun Wang, Chenchen Guo, Bo-Zhen Chen, Mingjuan Ji

Antiviral Res. 2015 Jan;113:79-92.

PMID: 25449363

1

Gateways to Clinical Trials

M Bayes, X Rabasseda, J R Prous

Methods Find Exp Clin Pharmacol. 2002 Apr;24(3):159-84.

PMID: 12087878

1

Resolution of the Interaction Mechanisms and Characteristics of Non-Nucleoside Inhibitors of Hepatitis C Virus Polymerase

Johan Winquist, Eldar Abdurakhmanov, Vera Baraznenok, Ian Henderson, Lotta Vrang, U Helena Danielson

Antiviral Res. 2013 Mar;97(3):356-68.

PMID: 23305851

  • Verification code
Contact Us

Send Us a Request

What is your specific need? We will do everything we can to meet your expectations.
Online Inquiry

Online Inquiry

For any inquiry, question or recommendation, please call: or fill out the following form.

  • Verification code

Head Office

  • Tel:
  • Email:

Follow us on

qrcode